Currently out of the existing stock ratings of Gil Blum, 310 are a BUY (98.41%), 5 are a HOLD (1.59%).

Gil Blum

Work Performance Price Targets & Ratings Chart

Analyst Gil Blum, currently employed at NEEDHAM, carries an average stock price target met ratio of 21.89% that have a potential upside of 53.67% achieved within 113 days. Previously, Gil Blum worked at TRUIST.

Gil Blumā€™s has documented 600 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RCKT, Rocket Pharmaceuticals at 28-Feb-2025.

Wall Street Analyst Gil Blum

Analyst best performing recommendations are on CTIC (CTI BIOPHARMA CORP).
The best stock recommendation documented was for GTHX (G1 THERAPEUTICS) at 6/25/2024. The price target of $6 was fulfilled within 43 days with a profit of $3.8 (172.73%) receiving and performance score of 40.17.

Average potential price target upside

AVRO AVROBIO GBIO Generation BioĀ Co TSHA Taysha Gene TherapiesĀ  FOLD Amicus Therapeutics AUTL Autolus Therapeutics Ltd RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics AGLE Aeglea Bio Therapeutics GTHX G1 Therapeutics NRIX Nurix TherapeuticsĀ  NXTC NextCureĀ  MREO Mereo BioPharma Group PLC ADR IMAB I-Mab SELB Selecta Biosciences STTK Shattuck LabsĀ  GMDA Gamida Cell Ltd CTIC CTi Biopharma Corp ACLX Arcellx GERN Geron CELC Celcuity LLC CRSP Crispr Therapeutics AG NKTX NkartaĀ  RXRX Recursion Pharmaceuticals IMCR Immunocore Holdings Ltd FATE Fate Therapeutics TCRX Tscan Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$2

$0.6 (42.86%)

1 years 2 months 13 days ago
(18-Dec-2023)

0/2 (0%)

$0.7 (53.85%)

Buy

$2

$0.6 (42.86%)

$36

1 years 7 months 18 days ago
(13-Jul-2023)

0/2 (0%)

$0.59 (41.84%)

Hold

$2

$0.6 (42.86%)

$2

1 years 7 months 19 days ago
(12-Jul-2023)

1/3 (33.33%)

$0.57 (39.86%)

7

Buy

2 years 2 months 24 days ago
(07-Dec-2022)

0/2 (0%)

$13.44 (140.59%)

Buy

2 years 9 months 14 days ago
(17-May-2022)

0/1 (0%)

$19.05 (212.85%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Gil Blum is most bullish on?

Potential upside of $95.25 has been obtained for SRPT (SAREPTA THERAPEUTICS)

Which stock is Gil Blum is most reserved on?

Potential downside of -$0 has been obtained for STTK (SHATTUCK LABSĀ )

What Year was the first public recommendation made by Gil Blum?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?